The United Kingdom and the United States have concluded a major trade agreement that will keep zero duties on British pharmaceutical products going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase funding on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these crucial goods will stay at nothing for a duration of 36 months.
This agreement comes after recent statements to significantly raise duties on patented pharmaceutical products, with increases mentioned up to 100%.
"This agreement with the United Kingdom reinforces the international landscape for innovative medicines and brings long-overdue equity to transatlantic medicine commerce," a statement noted.
Commercial Significance
Drugs represent one of the Britain's largest exports to the America, which is easily the primary buyer for large British pharmaceutical firms.
Statistics show that in the year leading up to the third quarter, the UK exported pharmaceutical products totaling billions to the US. This figure represented nearly one-fifth of British export trade in that span.
"This agreement secures employment, increases investment and paves the way for the UK to become a international leader for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The pact entails several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it considers new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to double total public funding on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be limited at 15%. In the past, rebates exceeded 20%.
Broader Context
The pact takes place against a protracted dispute between the drug companies and the British authorities over drug pricing and approval rates.
These tensions were heightened by claims that American customers were charged significantly more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the past decade.
